Novartis has acquired San Diego-based preclinical biotech DTx Pharma for $500 million, the Swiss pharma announced Monday. The deal also includes additional potential payments of up to $500 million upon completion of certain milestones.
SAN DIEGO, June 7, 2023 /PRNewswire/ -- DTx Pharma, a biotechnology company addressing the delivery challenges of oligonucleotide therapeutics with its Fatty Acid Ligand Conjugated OligoNucleotides (FALCON™) platform, today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to DTx-1252, an investigational FALCON small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A). CMT1A is a progressive, neuromuscular, autosomal-dominant disease that leads to life-long loss of muscle function and disability.
SAN DIEGO--(BUSINESS WIRE)--DTx Pharma, Inc. (DTx), a privately-held California biotechnology company developing novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Dr. Michael Huang as its Chief Medical Officer. Dr. Huang will provide leadership and supervision for DTx Pharma’s pipeline of clinical development programs.
SAN DIEGO--(BUSINESS WIRE)--DTx Pharma, Inc. (DTx), a privately held California-based biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, today announced that it has appointed Kathie M. Bishop, PhD, to its Board of Directors.
DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., Chief Executive Officer, will host virtual one-on-one meetings at the 2021 BMO BioPharma Day: Spotlight on Rare Disease and Ophthalmology on June 22, 2021. Dr. Suckow will also participate on an ophthalmology panel at 8:30 AM EST on the same day.
DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Jill Howe as Chief Financial Officer. Ms. Howe brings proven capabilities in private and public financial management, and will oversee all aspects of DTx’s finances.
SAN DIEGO, March 1, 2021 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today the completion of a $100 million Series B financing.
SAN DIEGO, Nov. 25, 2020 /PRNewswire/ -- DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today that Arthur T. Suckow, Ph.D., CEO of DTx Pharma, will be presenting a company overview and hosting one-on-one meetings at the following virtual conferences: